Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769223 · ClinicalTrials.gov registry record
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
A clinical trial of Prostate Cancer and Radiation Toxicity, sponsored by University of California, San Francisco.
- Active
- Registry status
- 3,561
- Enrollment target
- 1
- Study location
NCT00769223: Active study of Prostate Cancer and Radiation Toxicity, sponsored by University of California, San Francisco.
NCT00769223 is a study of Prostate Cancer and Radiation Toxicity that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 3,561 participants, above the 603-participant average among 735 other Prostate Cancer trials with a reported enrollment target (491% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00769223, a study of Prostate Cancer and Radiation Toxicity, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- 3,561 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.
Primary Outcome
The investigator will be analyzing the effect of baseline patient and clinical features such as age, Gleason score, PSA, clinical stage and percent positive biopsies on survival as well as quality of life parameters including potency, continence, and American Urological Association (AUA) symptoms scores
Conditions Studied
Interventions
- OTHER medical chart review
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- RADIATION brachytherapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,561 participants |
| Start Date | 1993-02-25 |
| Est. Completion | 2026-01-31 |
What the registry record for NCT00769223 still lists
NCT00769223 is an observational study that tracks outcomes without assigning an intervention. Its 3,561 participants enrollment target places it among the larger protocols in the corpus, above the 603-participant average among 735 other Prostate Cancer trials with a reported enrollment target (491% higher).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which medical chart review is the first listed.
NCT00769223 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00769223 about?
NCT00769223 is a clinical study titled "Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer". RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinica...
What is the current status of trial NCT00769223?
This trial is currently active not recruiting. The enrollment target is 3,561 participants. The study started on 1993-02-25. Estimated completion is 2026-01-31.
What conditions does trial NCT00769223 study?
This clinical trial studies the following conditions: Prostate Cancer, Radiation Toxicity.
What interventions are being tested in trial NCT00769223?
The interventions under investigation include: medical chart review (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00769223?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769223 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00769223's enrollment target sits among peer trials
3,561 15th of 735 higher than 721 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06429787 · 3,574 participants
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- NCT03199651 · 3,584 participants · NA
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI